LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Azacitidine for Injection. Fresenius Kabi Azacitidine for Injection is available ...

Mylan announced the launch of Azacitidine for Injection, the generic version of Celgene's Vidaza Injection. Vidaza Injection is indicated for the treatment of the five French-American-British (FAB) ...

One cancer drug shortage has ended and at least 14 oncology drugs are in short supply, according to the FDA, the American Society of Health-System Pharmacists and physicians. Azacitidine injections: ...

BOULDER, Colo., Aug. 29 -- Pharmion Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oral Azacitidine in the treatment of ...

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...

Dexamethasone sodium phosphate injection, USP 10 mg/mL, azacitidine 100 mg, carboprost tromethamine injection, USP 250 mcg/mL, and atropine sulfate injection, USP 0.5 mg/5 mL, have received ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug in a new class of compounds, ...

The drug azacitidine dramatically improves the survival of patients who have high-risk forms of myelodysplastic syndromes (MDS), according to an Article published Online First and in the March issue ...

Hikma is introducing azacitidine for injection, in a dosage strength of 100 mg. The product is the generic of Celgene’s Vidaza. It is indicated for treatment of patients with the following ...

* Received an approval from the United States Food & Drug Administration for Azacitidine - Injection Anda of SEZ formulations facility situated at Jadcherla Source text: bit.ly/2doO3Sd Further company ...

Amer Zeidan, MBBS, MHS: Hypomethylating agents [HMA] are the most commonly used modality for patients with high-risk MDS [myelodysplastic syndrome]. In the United States, they're approved for patients ...